Generic drug industry blue ribbon panel
Executive SummaryLead-off speakers at June 20 hearing are Center for Drug Evaluation and Research Director Carl Peck, MD, and Office of Generic Drugs Acting Director Bruce Burlington, MD, followed by speakers representing the generic industry, testing labs, health insurers and medical professional societies. Established by the Generic Pharmaceutical Industry Association and chaired by former PMA President Lewis Engman, the panel convenes at 9:00 a.m. at the Georgetown University Hotel and Conference Center in Washington, D.C.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.